Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy.

ABSTRACT: Oesophageal adenocarcinoma is a poor prognosis cancer and the molecular features underpinning response to treatment remain unclear. We investigate whole genome, transcriptomic and methylation data from 115 oesophageal adenocarcinoma patients mostly from the DOCTOR phase II clinical trial (Australian New Zealand Clinical Trials Registry-ACTRN12609000665235), with exploratory analysis pre-specified in the study protocol of the trial. We report genomic features associated with poorer overall survival, such as the APOBEC mutational and RS3-like rearrangement signatures. We also show that positron emission tomography non-responders have more sub-clonal genomic copy number alterations. Transcriptomic analysis categorises patients into four immune clusters correlated with survival. The immune sup

SUBMITTER: M Naeini M 

PROVIDER: S-EPMC10232490 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature